Apollo Endosurgery, Inc.
12
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
16.7%
2 terminated/withdrawn out of 12 trials
83.3%
-3.2% vs industry average
0%
0 trials in Phase 3/4
70%
7 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
ORBERA365 Post-Marketing Clinical Follow-up Study
Role: lead
Apollo Overstitch, a Treat and Resect Model
Role: collaborator
Endoscopic Suturing (ES) Registry
Role: collaborator
ORBERA™ Post-Approval Study
Role: lead
A Post-approval LAP-BAND® Lower Body Mass Index (LBMI) Study
Role: lead
HERO Study: Helping Evaluate Reduction in Obesity
Role: lead
Endoscopic Suturing for Primary Obesity Treatment
Role: collaborator
A Study of BioEnterics® Intragastric Balloon (BIB®) System to Assist in the Weight Management of Obese Subjects
Role: lead
Effectiveness and Safety Study of LAP-BAND Treatment in Subjects With BMI >/= 30 kg/m2 and < 40 kg/m2
Role: lead
LAP-BAND AP Early Experience Trial (APEX)
Role: lead
Feasibility Trial to Evaluate the Ability of the SuMO Tissue Access and Resection System
Role: collaborator
Effectiveness and Safety Study of LAP-BAND Treatment for Obese Adolescents
Role: lead
All 12 trials loaded